Remove 2011 Remove Pharma Remove Pharmaceutical products Remove Safety
article thumbnail

Everything You Need to Know About Market Access in China

PM360

Given China’s status as the world’s second most populous nation and an economic powerhouse, it represents both a monumental market opportunity and a dynamic arena of challenges for pharmaceutical products. Regulatory body – NMPA : all pharmaceutical products sold in the Chinese market need to be granted market authorization by NMPA.

Marketing 105
article thumbnail

Taming cardiovascular risk: the promise of LDL cholesterol lowering therapeutics

European Pharmaceutical Review

Dr Michael Davidson is CEO of biotech company NewAmsterdam Pharma. We are hopeful that NewAmsterdam Pharma is part of that solution with obicetrapib.” NewAmsterdam Pharma is moving forward into our Phase III trials in the high LDL populations and ultimately, we want to show the benefit of obicetrapib on reducing cardiovascular events.

Pharma 74